CymaBay Therapeutics Inc (USD)
CBAY
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range1.44 | 1.52
52-Wk Range |
Last Close1.48
Mkt Cap (m)101.95
Dividend yield-
ISINUS23257D1037
Volume2,698,949
Exchange VenueNAS

Company Profile

CymaBay Therapeutics Inc is an American biotechnology enterprise. Its product candidates include Arhalofenate, MBX-8025, and MBX-2982, which are meant to combat serious metabolic diseases.

Key Information
Price/Earning-
Price/Book0.55
Price/Sales-
P/CF-
Rev Growth (3 year avg)0.00
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-57.63
Debt/Equity0.01

Documents

Prospectus
en 06/03/2019
Annual Report
en 31/12/2019

Financials

Income Statement
USD201420152016201720182019
Revenue (m)10
Operating Income (m)-24-26-26-21-73-103
Net Income (m)-32-16-27-28-73-103
Basic EPS-2.65-0.82-1.14-0.79-1.25-1.53
Avg. Diluted Shares Outstanding (m)121923355867
Balance Sheet
USD201420152016201720182019
Current Assets (m)374319104182203
Non Current Assets (m)1153
Total Assets (m)374319104187206
Current Liabilities (m)2069161418
Total Liabilities (m)------
Total Equity (m)1428485170186
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)-21-23-23-20-55-98
Capital Expenditure (m)--1
Figures are quoted in USD unless stated otherwise
-
No change
$
1.48
Last Price